Michel Dahan is SVP, Chief Operating Officer of Akebia Therapeutics, Inc.. Currently has a direct ownership of 672,092 shares of AKBA, which is worth approximately $1.12 Million. The most recent transaction as insider was on May 13, 2024, when has been sold 34,840 shares (Common Stock) at a price of $1.26 per share, resulting in proceeds of $43,898. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 672K
0% 3M change
17.08% 12M change
Total Value Held $1.12 Million

Michel Dahan Transaction History

Date Transaction Value Shares Traded Shares Held Form
May 13 2024
SELL
Open market or private sale
$43,898 $1.26 p/Share
34,840 Reduced 4.93%
672,092 Common Stock
Feb 29 2024
SELL
Open market or private sale
$13,684 $1.58 p/Share
8,661 Reduced 1.21%
706,932 Common Stock
Feb 27 2024
SELL
Open market or private sale
$16,330 $1.52 p/Share
10,744 Reduced 1.48%
715,593 Common Stock
Jan 31 2024
BUY
Grant, award, or other acquisition
-
149,300 Added 17.05%
726,337 Common Stock
May 25 2023
SELL
Open market or private sale
$116,483 $1.22 p/Share
95,478 Reduced 14.26%
574,037 Common Stock
May 24 2023
BUY
Grant, award, or other acquisition
-
200,000 Added 23.0%
669,515 Common Stock
May 12 2023
BUY
Grant, award, or other acquisition
-
200,000 Added 29.87%
469,515 Common Stock
Mar 01 2023
SELL
Open market or private sale
$17,962 $0.88 p/Share
20,412 Reduced 7.04%
269,515 Common Stock
Feb 27 2023
SELL
Open market or private sale
$8,172 $0.81 p/Share
10,090 Reduced 3.36%
289,927 Common Stock
Mar 01 2022
SELL
Open market or private sale
$32,502 $2.17 p/Share
14,978 Reduced 4.8%
297,017 Common Stock
Feb 28 2022
SELL
Open market or private sale
$14,093 $2.15 p/Share
6,555 Reduced 2.47%
258,995 Common Stock
Feb 28 2022
BUY
Grant, award, or other acquisition
-
50,000 Added 13.93%
308,995 Common Stock
Apr 01 2021
SELL
Open market or private sale
$4,117 $3.4 p/Share
1,211 Reduced 0.45%
265,550 Common Stock
Mar 16 2021
BUY
Grant, award, or other acquisition
-
11,648 Added 4.18%
266,761 Common Stock
Mar 01 2021
SELL
Open market or private sale
$49,460 $3.4 p/Share
14,547 Reduced 5.39%
255,113 Common Stock
Feb 26 2021
BUY
Grant, award, or other acquisition
-
62,000 Added 18.69%
269,660 Common Stock
MD

Michel Dahan

SVP, Chief Operating Officer
Cambridge, MA

Track Institutional and Insider Activities on AKBA

Follow Akebia Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKBA shares.

Notify only if

Insider Trading

Get notified when an Akebia Therapeutics, Inc. insider buys or sells AKBA shares.

Notify only if

News

Receive news related to Akebia Therapeutics, Inc.

Track Activities on AKBA